Intellia to Report Pivotal Phase 3 HAELO Data for Lonvoguran Ziclumeran on April 27
NTLA has more than doubled off its 52-week low of $6.83 on elevated volume (2.0× avg).
Summary
Intellia Therapeutics announced it will report topline data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran in hereditary angioedema (HAE) on April 27, 2026. This announcement sets a critical near-term catalyst for the company, as Phase 3 results are pivotal for regulatory approval and commercialization. Given Intellia's $1.6 billion market cap, the outcome of this trial is highly material and could significantly impact the stock price. Traders will be closely watching for these results, which will be discussed in a webcast on the same day.
At the time of this announcement, NTLA was trading at $15.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $6.83 to $28.25. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.